• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance

    Thumbnail
    View/ Open
    oncotarget-03-1068.pdf (4.595Mb)

    Show full item record
    
    Author
    McCubrey, James A.; Steelman, Linda S.; Chappell, William H.; Abrams, Stephen L.; Franklin, Richard A.; Montalto, Giuseppe; Cervello, Melchiorre; Libra, Massimo; Candido, Saverio; Malaponte, Grazia; Mazzarino, Maria C.; Fagone, Paolo; Nicoletti, Ferdinando; Bäsecke, Jörg; Mijatovic, Sanja; Maksimovic-Ivanic, Danijela; Milella, Michele; Tafuri, Agostino; Chiarini, Francesca; Evangelisti, Camilla; Cocco, Lucio; Martelli, Alberto M.
    Abstract
    The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Targeting these pathways is often complex and can result in pathway activation depending on the presence of upstream mutations (e.g., Raf inhibitors induce Raf activation in cells with wild type (WT) RAF in the presence of mutant, activated RAS) and rapamycin can induce Akt activation. Targeting with inhibitors directed at two constituents of the same pathway or two different signaling pathways may be a more effective approach. This review will first evaluate potential uses of Raf, MEK, PI3K, Akt and mTOR inhibitors that have been investigated in pre-clinical and clinical investigations and then discuss how cancers can become insensitive to various inhibitors and potential strategies to overcome this resistance.
    URI
    http://hdl.handle.net/10342/7913
    Date
    2012-10-20
    Citation:
    APA:
    McCubrey, James A., & Steelman, Linda S., & Chappell, William H., & Abrams, Stephen L., & Franklin, Richard A., & Montalto, Giuseppe, & Cervello, Melchiorre, & Libra, Massimo, & Candido, Saverio, & Malaponte, Grazia, & Mazzarino, Maria C., & Fagone, Paolo, & Nicoletti, Ferdinando, & Bäsecke, Jörg, & Mijatovic, Sanja, & Maksimovic-Ivanic, Danijela, & Milella, Michele, & Tafuri, Agostino, & Chiarini, Francesca, & Evangelisti, Camilla, & Cocco, Lucio, & Martelli, Alberto M.. (October 2012). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance. Oncotarget, (3:10), p.. Retrieved from http://hdl.handle.net/10342/7913

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    McCubrey, James A., and Steelman, Linda S., and Chappell, William H., and Abrams, Stephen L., and Franklin, Richard A., and Montalto, Giuseppe, and Cervello, Melchiorre, and Libra, Massimo, and Candido, Saverio, and Malaponte, Grazia, and Mazzarino, Maria C., and Fagone, Paolo, and Nicoletti, Ferdinando, and Bäsecke, Jörg, and Mijatovic, Sanja, and Maksimovic-Ivanic, Danijela, and Milella, Michele, and Tafuri, Agostino, and Chiarini, Francesca, and Evangelisti, Camilla, and Cocco, Lucio, and Martelli, Alberto M.. "Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance". Oncotarget. 3:10. (.), October 2012. April 14, 2021. http://hdl.handle.net/10342/7913.
    Chicago:
    McCubrey, James A. and Steelman, Linda S. and Chappell, William H. and Abrams, Stephen L. and Franklin, Richard A. and Montalto, Giuseppe and Cervello, Melchiorre and Libra, Massimo and Candido, Saverio and Malaponte, Grazia and Mazzarino, Maria C. and Fagone, Paolo and Nicoletti, Ferdinando and Bäsecke, Jörg and Mijatovic, Sanja and Maksimovic-Ivanic, Danijela and Milella, Michele and Tafuri, Agostino and Chiarini, Francesca and Evangelisti, Camilla and Cocco, Lucio and Martelli, Alberto M., "Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance," Oncotarget 3, no. 10 (October 2012), http://hdl.handle.net/10342/7913 (accessed April 14, 2021).
    AMA:
    McCubrey, James A., Steelman, Linda S., Chappell, William H., Abrams, Stephen L., Franklin, Richard A., Montalto, Giuseppe, Cervello, Melchiorre, Libra, Massimo, Candido, Saverio, Malaponte, Grazia, Mazzarino, Maria C., Fagone, Paolo, Nicoletti, Ferdinando, Bäsecke, Jörg, Mijatovic, Sanja, Maksimovic-Ivanic, Danijela, Milella, Michele, Tafuri, Agostino, Chiarini, Francesca, Evangelisti, Camilla, Cocco, Lucio, Martelli, Alberto M.. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance. Oncotarget. October 2012; 3(10) . http://hdl.handle.net/10342/7913. Accessed April 14, 2021.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback